Mizuho Reiterates Buy Rating on The Chemours Company
Mizuho maintains its buy rating for Chemours with a $25 price target, a 21.83% upside from the current price.
Key Points
- Mizuho reiterated its buy rating on The Chemours Company, setting a $25 price target on July 1, 2026.
- Mizuho's $25 price target implies 21.83% upside from The Chemours Company's ($CC) current $20.52 share price.
- Shares of Chemours traded around $20.52 on Wednesday, with a market cap of approximately $3.09 billion.
- Chemours insiders recently bought shares, and analysts have set price targets ranging from $21 to $30.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reiterated its buy rating on The Chemours Company (NYSE:CC), maintaining a price target of $25. The announcement came on July 1, 2026, as shares of Chemours traded near $20.52 on the same day.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in The Chemours Company
BlackRock, Inc. reduced its holdings in Chemours by 3.49 million shares, ending with 22.39 million shares valued at roughly $493.2 million, a 13.5% decrease. Vanguard Portfolio Management LLC opened a new position with 10.33 million shares worth about $227.5 million. Similarly, Vanguard Capital Management LLC initiated a stake of 6.77 million shares valued at approximately $149.2 million. State Street Corp made a slight reduction, selling 15,195 shares to hold 6.12 million shares worth $134.9 million. Ameriprise Financial Inc increased its stake by 331,507 shares, reaching 4.84 million shares valued at $106.6 million.
The Chemours Company Stock Up 31.4%
Shares of NYSE:CC traded near $20.52 on Wednesday. The Chemours Company has a market capitalization of about $3.09 billion. It features a forward P/E ratio of 9.14 and a beta of 1.393. The stock's 52-week range spans from $10.44 to $28.67, with a 50-day moving average of $23.06 and a 200-day moving average of $17.57. The company has a current ratio of 1.82, a quick ratio of 0.819, and a debt-to-equity ratio of 2033.8.
$CC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Chemours reported revenue of approximately $5.82 billion, showing a slight growth of 1%. The company, however, posted a net margin of -7.0% and a return on equity of -103.0%. The next earnings release is scheduled for August 4, 2026.
Dividend
Chemours pays an annual dividend of $0.35 per share, yielding about 1.71%. The dividend payout ratio stands at 5.56%.
Insider Buying and Selling at The Chemours Company
On May 6, 2026, several insiders, including Leslie Turner, George Brokaw, Pamela Fletcher, Joseph Daniel Kava, Livingston Satterthwaite, and Alister Cowan, each purchased 7,182 shares of Chemours. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On July 1, 2026, Mizuho maintained its buy rating for Chemours, setting a price target of $25. Previously, on May 21, 2026, JP Morgan maintained a hold rating with a $22 target. Morgan Stanley also maintained a hold rating with a $21 target on May 11, 2026. RBC Capital, UBS, and Truist Securities have all maintained buy ratings with targets ranging from $27 to $30. The consensus among nine analysts is a buy recommendation, with an average target price of approximately $26.33.
About The Chemours Company
The Chemours Company, headquartered in Wilmington, Delaware, provides performance chemicals globally. It operates in the sectors of Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Chemours' offerings include refrigerants, TiO2 pigment, and advanced materials under brands like Freon, Opteon, Ti-Pure, Teflon, and Nafion. The company, led by CEO Denise M. Dignam, employs around 5,700 people.
Bottom Line
The Chemours Company continues to draw attention from analysts and institutional investors, with Mizuho reiterating its buy rating and setting a $25 price target. Investors should note that while institutional holdings and insider activity provide insights, 13F filings and analyst ratings are backward-looking and may not reflect current conditions. As always, perform due diligence before making investment decisions.
Get The Chemours Company alerts
New 13F filings, insider trades, and analyst moves on $CC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.